Search for Clinical Trial Results

Sponsored By

Gaucher Disease Type 1 - 25 Studies Found

Status Study
Recruiting Study Name: Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
Condition: Gaucher Disease Type 1
Date: 2015-08-21
Interventions: Drug: N-acetylcysteine 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
Completed Study Name: Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease
Condition: Type 1 Gaucher Disease
Date: 2006-04-26
Interventions: Drug: miglustat miglustat oral capsules 100mg three times daily (TID)
Not yet recruiting Study Name: Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease
Condition: Type 1 Gaucher Disease
Date: 2016-09-23
Interventions: Drug: Elelyso 60 units/kg All patients receive Elelyso 60 units/kg.
Completed Study Name: Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease
Condition: Gaucher Disease Type 1
Date: 2014-01-27
Interventions: Device: BeamMed Speed-of-Sound bone strength test at forearm BeamMed Speed-of-Sound bone strength test a
Terminated Study Name: A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101
Condition: Type 1 Gaucher Disease
Date: 2009-04-02
Interventions: Drug: AT2101 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days
Completed Study Name: Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
Condition:
  • Gaucher Disease, Type 1
  • Cerebroside Lipidosis Syndrome
  • Date: 2006-08-15
    Interventions: Drug: Cerezyme Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
Recruiting Study Name: GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3
Condition: Gaucher Disease Type 1-Gaucher Disease Type 3
Date: 2016-07-20
Interventions: Drug: GZ402671 Other Name: Venglustat
Recruiting Study Name: The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Condition:
  • Gaucher Disease Type 1
  • Gaucher Disease Type 3

Date: 2015-07-28
Interventions: Drug: Velaglucerase alfa Enzyme replacement therapy
Completed Study Name: A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients
Condition: